Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study
View abstract on PubMed
Summary
This summary is machine-generated.Predictive and protective factors for colorectal cancer in chronic ulcerative colitis (CUC) were identified. Surveillance colonoscopies and anti-inflammatory drugs may reduce cancer risk, while pseudopolyps increase it.
Area Of Science
- Gastroenterology
- Oncology
- Epidemiology
Background
- Colorectal cancer (CRC) risk is elevated in chronic ulcerative colitis (UC) patients.
- Predictive and protective factors for CRC in UC are not well-defined.
- The roles of surveillance colonoscopy and 5-aminosalicylic acid (5-ASA) therapy in mitigating CRC risk are debated.
Purpose Of The Study
- To identify predictive and protective factors for colorectal cancer in patients with chronic ulcerative colitis.
- To evaluate the association of surveillance colonoscopy, 5-ASA therapy, pseudopolyps, and other anti-inflammatory medications with CRC risk in UC.
Main Methods
- A case-control study involving 188 patients with UC-related cancer and matched controls.
- Conditional logistic regression analysis was used to identify independent predictors of CRC.
- Variables were adjusted for age at colitis diagnosis and colitis duration.
Main Results
- A history of pseudopolyps was a significant predictor of CRC (OR, 2.5).
- Surveillance colonoscopy (OR, 0.4) and use of anti-inflammatory medications including corticosteroids (OR, 0.4), aspirin (OR, 0.3), and NSAIDs (OR, 0.1) were associated with reduced CRC risk.
- 5-ASA agents showed a trend towards reduced risk (OR, 0.4), but was not statistically significant after 5 years. Smoking also showed a protective effect (OR, 0.5).
Conclusions
- Surveillance colonoscopy and anti-inflammatory medications may reduce CRC risk in chronic ulcerative colitis patients.
- A history of postinflammatory pseudopolyps is a significant predictive factor for CRC in UC.
- Further research is needed to clarify the long-term impact of 5-ASA therapy on CRC risk.